New genomic techniques (NGT) like CRISPR/Cas are changing plant breeding. With the regulation (BE) 2026/1388 The EU has created its own set of rules for NGT plants. She is on 16. July 2026 entered into force. The general legal framework for approval and labeling applies from 17. July 2028; The regulations on patent transparency, however, already apply now. For breeders, This has immediate consequences for seed companies and applicants for biotechnological inventions.
What the patent rules provide
- Disclosure of existing patents: Anyone who classifies a plant as an NGT plant of the category 1 requested, must specify, which patents or patent applications the plant has, their material or the process.
- Public database: This information is published in a publicly accessible database, as well as information on readiness, to grant licenses.
- Voluntary License Declarations: Patent holders can declare, to license on fair and reasonable terms. This makes access easier for breeders.
- Observation of the effects: The Commission examines the impact of patents on innovation and access to plant material and may propose further measures.
Patent law itself remains unchanged: Essentially biological processes and plants obtained exclusively through them are not patentable. On the other hand, technical genome editing processes and the features they create can enjoy patent protection, if novelty, inventive step and commercial applicability exist.
For practice: What applicants and breeders should do now
- Capture portfolio: Which own patents and applications concern NGT features, Process or plant material?
- Determine licensing strategy: Decide, whether and under what conditions willingness to license should be declared.
- Check freedom to operate: Before developing or marketing an NGT variety, research third-party intellectual property rights.
- Formulate registrations carefully: Align claims with technical processes and features and explain the distinction from essentially biological processes.
- Think about plant variety protection: Patent- and plant variety protection complement each other; the strategy should cover both intellectual property rights.
Our patent attorneys advise on registration, Research and licensing of biotechnological inventions.

Leave a Reply